Rice University will launch online classes next week for small business leaders planning their recovery. Courtesy of Rice University

Houston small businesses and startups have a long road of recovery ahead of them, and Rice University and some of its partners want to help local entrepreneurs prepare for it.

Rice University's Susanne M. Glasscock School of Continuing Studies has partnered with the Ion — along with the Center for Houston's Future and Rice Alliance for Technology and Entrepreneurship — to launch the Back In Business Initiative. The program will begin with three courses in the week of April 20 to 24. The three courses are:

"Glasscock's mission has always been to provide education to the residents of Houston," says Robert Bruce, dean of the Glasscock School, in a news release. "We specialize in providing responsive, practical information that will help our constituents when and how they need it most. To assist our struggling Houston small business community during this crisis, we created this trilogy of courses to help analyze their current situation, use creative problem-solving and provide meaningful communications to help them weather this situation."

More classes will be added as needed. The classes have a $25 registration fee, and anyone can enroll online.

"Today's health crisis may have changed many aspects of our daily lives, but it has not affected our commitment to providing the right tools and education to help our community succeed," says Jan Odegard, senior director of academic and industry partnerships at the Ion, in the release. "We all have a role to play in meeting the challenge of COVID-19 and we are excited to be partnering with the Glasscock School of Continuing Studies to support Houston small businesses in this time of uncertainty."

The university also touts OpenRICE as a resource for businesses. The online education platform is available to the Houston community for free. Rice also has a 20 percent discount for all professional studies courses and programs enrollment — with the ability to postpone for up to a year without a fee. This deal runs through April 30.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”